Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab

被引：0
|
作者：
Lee, Min Young [1 ,2 ]
Lee, Woo In [1 ,2 ]
Kang, So Young [1 ,2 ]
Kim, Myeong Hee [1 ,2 ]
Park, Young Shil [2 ,3 ]
机构：
[1] Kyung Hee Univ, Sch Med, Dept Lab Med, 892 Dongnam Ro, Seoul 05278, South Korea
[2] Kyung Hee Univ Hosp Gangdong, 892 Dongnam Ro, Seoul 05278, South Korea
[3] Kyung Hee Univ, Sch Med, Dept Pediat, Seoul, South Korea
来源：
ANNALS OF LABORATORY MEDICINE | 2023年 / 43卷 / 01期
关键词：
D O I：
10.3343/alm.2023.43.1.96
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：96 / 99
页数：4
相关论文
共 50 条
  • [41] Factor IX assays in treated hemophilia B patients
    Pouplard, Claire
    Jeanpierre, Emmanuelle
    Lasne, Dominique
    Duchez, Veronique Le Cam
    Eschwege, Valerie
    Flaujac, Claire
    Galinat, Hubert
    Harzallah, Ines
    Proulle, Valerie
    Smahi, Motalib
    Sobas, Frederic
    Ternisien, Catherine
    Toulon, Pierre
    Voisin, Sophie
    Nougier, Christophe
    HEMATOLOGIE, 2020, 26 (01): : 18 - 34
  • [42] Factor VIII assays in haemophilia A patients treated with ReFacto™
    Sukhu, K
    Harrison, P
    Keeling, D
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (02) : 379 - 380
  • [43] Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays
    Valikhani, Amir
    Mirakhorly, Mojgan
    Namvar, Ali
    Rastegarlari, Ghasem
    Toogeh, Gholamreza
    Shirayeh, Fatemeh Vossough
    Ahmadinejad, Minoo
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (05)
  • [44] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
    Escobar, Miguel
    Bullano, Michael
    Mokdad, Ali G.
    Caicedo, Jorge
    Schultz, Bob G.
    Fan, Qi
    Verma, Sumit
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
  • [45] Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
    Mancuso, Maria Elisa
    Castaman, Giancarlo
    Pochopien, Michal
    Aballea, Samuel
    Drzewiecka, Aleksandra
    Hakimi, Zalmai
    Nazir, Jameel
    Fatoye, Francis
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1068 - 1075
  • [46] Chromogenic factor VIII activity assay
    Moser, Karen A.
    Funk, Dorothy M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (07) : 781 - 783
  • [47] Treatment changes in hemophilia A with chromogenic factor VIII assay implementation
    Al Moosawi, Muntadhar
    Nicolson, Hamish
    Wong, Steven K. W.
    Dallas, Karen L.
    Jackson, Shannon
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (02)
  • [48] Comparison of analytical performances of the automated chromogenic and one-stage factor VIII assays
    Herak, Desiree Coen
    Milos, Marija
    Prpic, Snjezana
    Zadro, Renata
    HAEMOPHILIA, 2018, 24 : 44 - 44
  • [49] ASSESSING FACTOR VIII ACTIVITY IN THE PRESENCE OF MIM8 VIA CHROMOGENIC ASSAYS
    Pickering, W.
    Robinson, M.
    Cogswell, C.
    Clausen, W. H. O.
    Ezban, M.
    HAEMOPHILIA, 2022, 28 : 26 - 26
  • [50] THE ECONOMIC IMPACT OF REDUCING BLEEDING WITH EMICIZUMAB IN PATIENTS WITH HEMOPHILIA A AND FACTOR VIII INHIBITORS - BRAZILIAN CASE
    Segre, N.
    Mata, V
    Martins, T. D. C.
    VALUE IN HEALTH, 2022, 25 (12) : S165 - S165
12345